ndovascular intervention is now considered to be a first-line option for the treatment of patients with symptomatic peripheral artery disease. 1, 2 The endovascular treatment landscape encompasses a broad range of interventions, and each option has unique advantages and disadvantages.
Bare metal stents usually yield better outcomes compared with percutaneous transluminal angioplasty alone 3, 4 but are associated with risk of postprocedural restenosis, thrombosis, and stent fracture. [5] [6] [7] Drugeluting stents and drug-coated balloons (DCBs) were developed to address some of these concerns, and meta-analyses of clinical trial data have shown that DCBs can support better long-term outcomes when compared with bare metal stents or percutaneous transluminal angioplasty alone (mean lesion length in DCB groups ranged 3.5-17.3 cm). 8, 9 DCBs have advantages over other endovascular procedures and are designed to prevent restenosis by inhibiting neointimal hyperplasia with paclitaxel that is deposited into the vessel wall on inflation. 10 The safety and effectiveness of DCBs in short symptomatic lesions (6-9 cm) of the superficial femoral (SFA) and popliteal arteries have been demonstrated in multiple clinical studies, including randomized controlled trials. [11] [12] [13] [14] [15] [16] [17] Data are more limited on the use of DCBs in long femoropopliteal lesions, which are especially challenging to treat. 18 Initial findings show encouraging patency rates at 1 year, with data available from a retrospective analysis, a single-center prospective series, and a prospective multicenter study. [19] [20] [21] The results from these studies suggest that DCBs are a promising option for long lesions, but there remains an unmet need for a study with the rigor of a prospective clinical trial that is also generalizable to real-world patients.
The IN.PACT Global Study was designed to evaluate the safety and effectiveness of a paclitaxel-coated DCB (IN.PACT Admiral, Medtronic Inc, Dublin, Ireland) in the treatment of real-world subjects with atherosclerotic femoropopliteal peripheral artery disease, including long lesions (≥15 cm) in the SFA and/or popliteal artery (P1-P3). Prespecified subjects who met the criteria for core-laboratory-adjudicated duplex ultrasound imaging formed an imaging cohort, which contained 3 subcohorts: de novo in-stent restenosis, long lesions (≥15 cm), and chronic total occlusion ≥5 cm.
To our knowledge, the long lesion imaging cohort is the largest group of real-world subjects that has been evaluated for DCB safety and effectiveness in long lesions (≥15 cm) in the SFA and/or popliteal artery (P1-P3). Herein, we report 12-month results.
METHODS
The data, analytic methods, and study materials may be made available to other researchers on request from the sponsor.
IN.PACT Global Study: Design, Subjects, and Treatment
A prospective analysis of DCBs for the treatment of long lesions (≥15 cm) was incorporated into the design of the IN.PACT Global Study, a prospective, multicenter, international, singlearm clinical trial assessing the safety and effectiveness of a paclitaxel-coated DCB for the treatment of real-world patients with intermittent claudication and/or rest pain because of obstructive disease of the femoropopliteal artery, including the full native SFA and/or full popliteal artery (P1-P3). Safety outcomes will be collected through 5 years, functional outcomes were collected through 3 years, and for patients in this cohort, duplex imaging was collected through 1 year or at reintervention.
A total of 1535 subjects were enrolled in the IN.PACT Global Study between April 2011 and March 2014 (Figure 1 ). The patient enrollment number was not predefined for specific statistical analyses but was kept open for up to 1500 subjects globally to ensure sufficient clinical outcome data to perform meaningful subset analyses and statistical analyses, especially those which may not be possible in smaller single-arm registries and randomized controlled trials. Overall screen failure rate was not captured in this cohort. Subjects were distributed among 3 cohorts: a clinical cohort, imaging cohort, and 150-mm DCB cohort. Subjects who qualified for enrollment in the clinical cohort (1416) were screened for eligibility in the imaging cohort and 1406 subjects were treated with DCB and included in this analysis. The imaging cohort was a part of the clinical cohort in which subjects underwent duplex ultrasonography (DUS; or angiography when DUS was not available) of all target lesions at 12 months (±2 months) after target treatment and at the time of any reintervention within 12 months to allow assessment of primary patency. The imaging cohort itself contained 3 prospectively defined subcohorts with prospectively planned analyses: de novo in-stent restenosis (166 subjects), long lesions ≥15 cm (179 subjects), and chronic total occlusions ≥5 cm (150 subjects). To be enrolled in the long lesion imaging cohort, subjects only needed to have 1 long lesion (≥15 cm; 179 subjects) at preprocedure baseline. The only subjects in the long lesion imaging cohort who were included in the analysis, however, were those in whom only long lesions were treated during the
WHAT IS KNOWN
• In patients with peripheral artery disease, longer femoropopliteal lesions are challenging to treat and a high reobstruction rate has to be expected.
• While drug-coated balloon have shown to be an effective modality for reducing restenosis in shortand moderate-length lesions, there is limited data on the use of drug-coated balloons in endovascular treatment of femoropopliteal lesions ≥15 cm.
WHAT THE STUDY ADDS
• One-year results from the long lesion imaging cohort of the IN.PACT Global Study demonstrate the safety and effectiveness of a drug-coated balloon to treat long femoropopliteal lesions.
index procedure (ie, no other types of lesions could have been treated during the index procedure; 157 subjects). Subjects with symptoms of intermittent claudication and/ or rest pain (Rutherford Clinical Category, 2-4) and angiographic evidence of occlusion or stenosis (length ≥2 cm) in the SFA and/or popliteal artery (including P1-P3) were eligible for enrollment in the IN.PACT Global Study. Subjects with multiple lesions were allowed.
See the Data Supplement for additional details on subject and target lesion enrollment criteria, reasons for provisional stenting, and use of preprocedural and procedural anticoagulant and antiplatelet medications.
Independent core laboratories analyzed all images, including DUS (VasCore, Massachusetts General Hospital Boston, MA) and angiography (SynvaCor Angiographic Core Lab, Springfield, IL). In cases where both angiography and DUS were available at the same assessment, angiography was preferentially used. An independent Clinical Events Committee (Syntactx Clinical Events Committee, New York, NY) adjudicated all major adverse events. The Clinical Events Committee was composed of 1 interventional cardiologist and 4 vascular surgeons with pertinent expertise but who were not participants in the study and did not have conflicts of interest. The Clinical Events Committee developed specific criteria that were applied to classify and adjudicate all events. Medtronic or their designee monitored all subjects in the long lesion imaging cohort with a focus on detection of adverse events and events related to end points.
The study protocol was approved by the institutional review board or ethics committee at each trial site. Informed consent was obtained from all subjects before enrollment. The trial was conducted in accordance with the Declaration of Helsinki, good clinical practice guidelines, and applicable laws as specified by all relevant governmental bodies.
Long Lesion Imaging Cohort Study End Points
The primary safety composite end point was freedom from device-and procedure-related mortality through 30 days and The imaging cohort was considered to be a part of the clinical cohort and contained 3 prospectively defined subcohorts, including long lesions (≥15 cm). Subjects with at least 1 lesion ≥15 cm could be enrolled in the long lesion imaging cohort (179 subjects), but analysis was restricted to subjects in whom lesions ≥15 cm were the only targets treated during the index procedure (157 subjects). CTO indicates chronic total occlusion; DCB, drug-coated balloon; and ISR, in-stent restenosis. *In the clinical cohort, 1406 subjects were treated with DCB.
freedom from major target limb amputation and clinicallydriven target vessel revascularization (TVR) within 12 months post index procedure. For the primary safety composite end point, clinically-driven TVR was assessed at the subject level and defined as the first event that required TVR in the subject. The primary effectiveness end point was 12-month primary patency, defined as freedom from clinically-driven target lesion revascularization (CD-TLR) and freedom from restenosis (DUS peak systolic velocity ratio ≤2.4). The Clinical Events Committee reviewed all TLR events to determine which were clinically driven, defined as any reintervention within the target lesion(s) because of symptoms or ankle-brachial index (ABI) decrease of ≥20% or >0.15 when compared with post index procedure baseline ABI. Secondary end points included the incidence of major adverse events (all-cause mortality, clinically-driven TVR, major target limb amputation, thrombosis at the target lesion site), CD-TLR, any TLR, and any TVR at 12 months. Other secondary end points included change in Rutherford Clinical Category, change in ABI, and level of walking impairment as assessed by the Walking Impairment Questionnaire (WIQ) at 12 months.
For definitions of acute periprocedural outcomes or categories of stent coverage, see Methods in the Data Supplement.
Long Lesion Imaging Cohort Subgroup Statistical Analysis
All analyses were based on the intent to treat principle, and all summaries were based on nonmissing assessments. Unless otherwise specified, all baseline demographics, clinical characteristics, and procedural characteristics were summarized on a subject basis; lesion characteristics were summarized on a lesion basis. For baseline characteristics, continuous variables were described as mean±SD; dichotomous and categorical variables were described as counts and proportions. The Kaplan-Meier method was used to evaluate time-to-event data for primary patency and CD-TLR for the 12-month follow-up period. The outcome analysis was performed at a subject level. For event rates that were expressed as a proportion, the number of subjects with an event was the numerator and the total number of subjects with at least 330 days of clinical follow-up was the denominator. For assessment of clinical characteristics at 12 months, subjects were required to have data at both baseline and 12 months but were not required to have a full 330 days of clinical follow-up. Statistical analyses were performed using SAS (SAS Institute, NC) version 9.4.
RESULTS

Baseline Subject and Lesion Characteristics
The IN.PACT Global Study enrolled 1535 subjects across 64 sites in >25 countries from Europe, the Middle East, Asia, Australia, Canada, and Latin America. Subjects with at least 1 lesion ≥15 cm were prospectively enrolled in the long lesion imaging cohort (179 subjects). Analysis was limited to subjects in which lesions ≥15 cm were the only targets treated during the index procedure (157 subjects). Because of protocol violations, 10 subjects classified as Rutherford Clinical Category 5 were enrolled and included in the analysis.
Independent core imaging laboratories and investigator sites used different imaging techniques to identify and evaluate lesions. This resulted in a different total number of target lesions, depending on whether the assessment was made by the independent core imaging laboratories or investigators. Independent core imaging laboratories determined that there were 164 target lesions among 157 subjects in the long lesion imaging cohort. Lesion characteristics that were assessed by imaging core laboratories, such as lesion length, were therefore based on a total of 164 lesions. The investigators, using individual site techniques, determined that there were 161 target lesions among 157 subjects. Lesion characteristics that were assessed by the investigators were therefore based on a total of 161 lesions.
Baseline demographics and characteristics of the long lesion imaging cohort (≥15 cm) are reported in Table 1 *Summaries are based on nonmissing assessments. In some cases, baseline demographic or clinical data were not available and therefore the total number of subjects for that variable will be <157.
†Defined as baseline creatinine ≥1.5 mg/dL. ‡Because of protocol violations, 10 subjects classified as Rutherford Clinical Category 5 were enrolled and included in the analysis.
§ABI indicates ankle-brachial index. For subjects with bilateral disease, ABI is included for each target limb. Tables 1 and 2 . Thirty-one subjects did not complete the study through the 13-month follow-up window: 11 withdrew consent, 14 were lost to follow-up, and 6 died (see section on Safety Outcomes Details on the use of preprocedural and procedural anticoagulant and antiplatelet medications can be found in Table I in the Data Supplement.
Effectiveness Outcomes
Acute periprocedural success was >99% by all measures. Device success was achieved with 99.5% (442/444) of devices used. Procedural success was achieved in 99.4% (159/160) of lesions, and clinical success was achieved in 99.4% (155/156) of subjects.
Primary patency by Kaplan-Meier estimate was 91.1% in the long lesion imaging cohort at 12 months (Figure 2, top) and 80.7% through the 13-month follow-up window. When subdivided into 2 lesion length categories, the Kaplan-Meier estimated 12-month primary patency rate was 97.7% for subjects with lesions 15 to 25 cm and 79.2% for subjects with lesions >25 cm (Figure 2, middle) . Freedom from CD-TLR by KaplanMeier estimate was 94.2% in the overall long lesion imaging cohort at 12 months.
Changes in Rutherford Clinical Category were observed (Figure 3 ). At baseline, 83.3% of subjects were category 2 to 3 (130/156) and 0% were category 0 to 1 (0/156). At 12 months, 19.2% (24/125) of subjects were category 2 to 3 and 76.8% (96/125) were category 0 to 1. The distribution of subjects among clinical categories was significantly different at 12 months compared with baseline (P<0.001).
Mean ABI was 0.669±0.232 in the long lesion imaging cohort at baseline (147 target limbs) and 0.878±0.206 mm Hg (113 target limbs) at 12 months. Mean change in ABI from baseline was 0.221±0.262 mm Hg (109 target limbs; P<0.001). Walking impairment after the index procedure was assessed with WIQ. The mean WIQ score was 28.6%±26.6% (152 subjects) in the long lesion imaging cohort at baseline and 71.4%±33.7% (119 subjects) at 12 months. Mean change in WIQ score from baseline was 44.0%±38.0% (116 subjects; P<0.001).
Provisional stents were implanted in 39.4% (63/160) of lesions ( *Independent core imaging laboratories determined that there were 164 target lesions among 157 subjects in the long lesion imaging cohort. Lesion characteristics that were assessed by imaging core laboratories were based on this total number of target lesions. The investigators, using individual site techniques, determined that there were 161 target lesions among 157 subjects. Lesion characteristics that were assessed by the investigators were therefore based on this total number of lesions.
†Summaries are based on nonmissing assessments. In some cases, baseline data were not available and therefore the total number of lesions for that variable will be <164 for data reported by independent core imaging laboratories or <161 for data reported by investigators. ‡Data reported by investigational sites. §Data reported by independent core imaging laboratories. ‖Severe calcification defined as calcification with circumference ≥180° (both sides of vessel at the same location) and length greater than or equal to half of the total lesion length.
¶Device success defined as successful delivery, inflation, deflation, and retrieval of the intact study balloon device without burst below the rated burst pressure. This analysis is device (balloon) based.
#Procedural success defined as residual stenosis of ≤50% for nonstented subjects or ≤30% for stented subjects by core laboratory assessment (site-reported estimate was used if core laboratory assessment was not available). This analysis is lesion based. **Clinical success defined as procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or target vessel revascularization) before discharge. This analysis is subject based. translesion gradient (0.6%; 1/160), flow-limiting dissection (20.6%; 33/160), and other (3.1%; 5/160). The provisional stent rate was higher among subjects with lesions >25 cm (50.9%; 30/59 lesions) compared with subjects with lesions 15 to 25 cm (32.7%; 33/101 lesions). Primary patency at 12 months by Kaplan-Meier estimate was 92.5% for subjects who received standalone DCB therapy (no provisional stent use) and 89.0% for subjects who were implanted with provisional stents (Figure 2, bottom) . The mean total stent length per subject was 168.4±99.0 mm (63 subjects).
Safety Outcomes
The 12-month primary safety composite end point was achieved in 94.0% (126/134) of subjects in the long lesion imaging cohort (Table 3) . Major adverse events were reported in 11.9% (16/134) of subjects. Thrombosis at the target lesion occurred in 3.7% (5/134) of subjects. There were no major target limb amputations and no device-or procedure-related deaths. The rate of all-cause death was 4.5% (6/134 subjects). Causes of death were respiratory failure at 191 days, subarachnoid hemorrhage and edema at 240 days, pneumonia at 295 days, biliary peritonitis at 305 days, and 2 cases of unknown causes at 108 days and 278 days. In all cases, death was unrelated to device, drug, or procedure.
DISCUSSION
The IN.PACT Global Study was a prospective, multicenter, international, single-arm clinical trial that evaluated the safety and effectiveness of a paclitaxel-coated DCB in a large population of subjects that were specifically enrolled to represent a real-world patient population. One of the core strengths of the IN.PACT Global ABI indicates ankle-brachial index; CD-TVR, clinically-driven target vessel revascularization; and TLR, target lesion revascularization. *An independent Clinical Events Committee adjudicated all major adverse events. †Event rates expressed as a proportion: number of subjects with an event=numerator, number of subjects with at least 330 days of clinical follow-up=denominator.
‡Clinically-driven TLR defined as any reintervention within the target lesion(s) because of symptoms or drop of ABI of ≥20% or >0.15 when compared with postindex procedure baseline ABI.
§The primary safety composite end point was freedom from device-and procedure-related mortality through 30 days and freedom from major target limb amputation and CD-TVR within 12 months postindex procedure.
‖Major adverse event defined as all-cause mortality, clinically-driven target vessel revascularization, major target limb amputation, and thrombosis at the target lesion site.
Study long lesion imaging cohort analysis was that it combined the rigor of a clinical trial, including independent adjudication of adverse events and independent analysis of angiography and DUS, with a subject population that represented the broad range of clinical variability seen in everyday practice.
Results from the long lesion imaging cohort analysis showed that the IN.PACT Admiral DCB is effective as a standalone therapy or with provisional stenting, up to 12 months after treatment in real-world subjects with long lesions (≥15 cm; mean length, 26.40±8.61 cm) in the native SFA and/or popliteal artery (P1-P3). Primary patency at 12 months by Kaplan-Meier estimate (91.1%) was consistent with the 12-month freedom from CD-TLR by Kaplan-Meier estimate (94.2%). These findings are especially robust when considered in the context of what has been published for other advanced endovascular options, including DCBs and drug-eluting stents for such a long lesion cohort. [19] [20] [21] [22] The findings seem favorable when compared with clinical trial reports of DCBs in short lesions (mean lengths, 6-9 cm), which are less challenging to treat, and for which primary patency rates have been reported to vary from 65% to 85% at 12 months. 14, 16, 23 A paclitaxel-coated stent has also been reported to achieve 12-month patency ≈80%, including subjects with long lesions (mean length, 22.6 cm). 24, 25 The long lesion imaging cohort was part of a larger full clinical cohort that included subjects with most types of complex femoropopliteal lesions and only excluded those with aneurysms and acute or subacute thrombotic occlusions. Similar imaging cohort analyses have been performed for subjects with de novo in-stent restenosis and chronic total occlusions (≥5 cm), the results of which are being published elsewhere. The rate of CD-TLR at 12 months in the long lesion imaging cohort (6.0%) was parallel with what was reported in the in-stent restenosis imaging cohort (7.3%; 131 subjects; mean lesion length, 17.17±10.47 cm), chronic total occlusion imaging cohort (11.3%; 126 subjects; mean lesion length, 22.83±9.76 cm; and full clinical cohort, 7.5%; 1406 subjects; mean lesion length, 12.09±9.54 cm). [26] [27] [28] Primary patency at 12 months was also similar between the imaging cohorts (by Kaplan-Meier estimate: 91.1% for long lesion, 88.7% for de novo in-stent restenosis, 85.3% for chronic total occlusions; not available for full clinical cohort as primary patency is imaging-based assessment data for all subjects was available only for imaging cohorts). 26, 28 The similarity of effectiveness outcomes across each of these imaging cohorts and the full clinical cohort support the use of the IN.PACT Admiral DCB in multiple types of complex lesion types that are commonly seen in everyday practice.
A key finding from the long lesion imaging cohort analysis was that a paclitaxel-coated DCB was highly effective as a standalone intervention. Provisional stenting was allowed if at least one of the following criteria was met despite repeated and prolonged balloon inflations: residual stenosis ≥50% (based on visual estimate), translesional gradient >10 mm Hg, or presence of a flow-limiting dissection. In the ≈60% of subjects who did not require provisional stenting, 12-month primary patency by Kaplan-Meier estimate was high (92.5%). The rate of provisional stenting in the long lesion imaging cohort was higher than what has been reported for DCBs in short lesions. 16, 19, 23 A correlation between stent rate, lesion length, and complexity is expected and was supported by the finding that 52.6% of subjects in the long lesion imaging cohort with lesions >25 cm required a provisional stent compared with 33.3% of those with lesions 15 to 25 cm, underscoring challenges with treating more complex lesions. Despite this difference, a spot stenting approach was sufficient in many subjects, and the overall effectiveness of the DCB did not differ between stented versus nonstented subjects.
Findings from the long lesion imaging cohort analysis showed that treatment with the IN.PACT Admiral DCB has a sustained clinical impact in real-world subjects with lesions ≥15 cm. Before the index procedure, all subjects were classified as Rutherford Clinical Category ≥2. Twelve months after the index procedure with DCB treatment, 77% of subjects were Rutherford Clinical Category 0 to 1. The difference in distribution of subjects among Rutherford Clinical categories between baseline and 12 months was statistically significant (P<0.001). Other functional outcome measures, such as change in ABI or WIQ, were also significantly improved at 12 months after intervention with IN.PACT Admiral (both P<0.001).
Paclitaxel-coated DCBs were safe for the treatment of subjects in the long lesion imaging cohort. There were no device-or procedure-related deaths and no major target limb amputations. The 12-month incidence of thrombosis was low (3.7%), similar to what has been reported for DCBs in short lesions, 14, 16 and lower than what has been reported for drug-eluting stents in long lesions. 24 Adverse event rates (for thrombosis, any TLR, and any TVR) were higher among subjects with lesions >25 cm compared with those with lesions 15 to 25 cm. The statistical significance of this separation was not determined in this analysis, but a potential difference in adverse event rates between lesion length groups could be multifactorial. Long lesion length, on its own, is a positive predictor of restenosis and TLR after stent placement, 6, 7, 29 but stent implantation is also associated with the induction of restenosis. 30 The rate of provisional stenting was higher among subjects with lesions >25 cm compared with those with lesions 15 to 25 cm, and increased rates of adverse events related to restenosis could be because of increased lesion length-associated risk, increased inflammation in the group associated with the higher rate of stenting, or a combination of both.
The IN.PACT Global Study long lesion imaging cohort analysis is unique in that it combined the all-comer approach of an observational registry with the rigor of a clinical trial. The IN.PACT Global Study applied permissive but deliberate eligibility criteria to facilitate the enrollment of a broad range of subjects with complex lesions (single or multiple lesions; unilateral or bilateral disease; any lesion ≥2 cm; de novo or restenotic). By evaluating a heterogeneous population, the long lesion imaging cohort results were designed to be generalizable to real-world patients that are encountered in everyday clinical practice. This is in contrast to traditional randomized controlled clinical trials that are often bound to strict eligibility criteria for the selection of a more consistent though less representative subject population. Although the IN.PACT Global Study long lesion imaging cohort analysis had the real-world feel of an observational registry, the study was designed with the scientific rigor of a clinical trial. This included the prospective planning of enrollment cohorts with prespecified analyses but especially the use of an independent Clinical Events Committee to adjudicate all major adverse events and independent core laboratories to analyze all angiography and DUS. The combination of these design strengths serves to bolster the findings of DCB safety and effectiveness in the long lesion imaging cohort, the largest group of real-world subjects with long lesions (≥15 cm) in the SFA and/or popliteal artery (P1-P3) evaluated to date.
Limitations of the Study
The IN.PACT Global Study long lesion imaging cohort was designed as a single-arm, nonrandomized study with no formal hypothesis testing. The findings were robust, and the rigor of the study was enhanced by the independent adjudication of adverse events and the independent analysis of angiography and DUS in prespecified cohorts, including the long lesion imaging cohort. The long lesion imaging cohort results are favorable when compared with previously published reports and generate hypotheses for further randomized controlled trials looking to compare the superiority of 1 treatment option versus another.
